# Phase III Trial of EBV-DNA-Guided Adaptive Immunotherapy for Advanced Nasopharyngeal Carcinoma

> **NCT07238569** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 516 (estimated)

## Conditions studied

- Nasopharyngeal Cancinoma (NPC)
- Nasopharangeal Cancer

## Interventions

- **DRUG:** Adebrelimab (PD-L1 inhibitor)
- **DRUG:** Cisplatin (100mg/m2)
- **RADIATION:** Intensity-modulated radiotherapy
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT07238569
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-01
- **Primary completion:** 2029-12-01
- **Final completion:** 2031-05-23
- **Target enrollment:** 516 (ESTIMATED)
- **Last updated:** 2025-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07238569

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07238569, "Phase III Trial of EBV-DNA-Guided Adaptive Immunotherapy for Advanced Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07238569. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*